45 recruiting, 41 not yet recruiting, 11 unknown, 2 active not recruiting. 101 Phase 2, 10 Phase 1, 1 Phase 3.
Follow Adebrelimab: new trials by email Literature Review of Adebrelimab trials Research Report on Adebrelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer Adebrelimab - Locally Advanced Resectable Rectal Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 155 | 2026-11-01 | 2026-10-30 |
| An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 660 | 2026-10-30 | 2026-11-09 |
| Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC Adebrelimab, Adjuvant treatment - Lung Neoplasm Malignant | Phase 2 | Not yet recruiting | Ruijin Hospital | 64 | 2026-10-20 | 2026-10-22 |
| Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy - Glioblastoma | Phase 2 | Not yet recruiting | Wei Jiang | 94 | 2026-10-01 | 2026-08-27 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Tongji Hospital | 70 | 2026-09-01 | 2026-10-08 |
| Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab, Trastuzumab Rezetecan (SHR-A1811), Adebrelimab - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Ming Chen | 105 | 2026-09-01 | 2026-09-23 |
| Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 36 | 2026-09-01 | 2026-09-18 |
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2026-08-30 | 2026-08-21 |
| A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC Adebrelimab, Trastuzumab rezetecan - NSCLC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 37 | 2026-08-20 | 2026-08-21 |
| A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer HRS-2329 Tablet, Nimotuzumab, HS-20093 - Pancreatic Cancer, RAS Mutations or Amplifications | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 80 | 2026-08-15 | 2026-08-31 |
| PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) Adebrelimab - Solid Cancer, Lymphopenia | Phase 2 | Recruiting | Second Affiliated Hospital of Soochow University | 65 | 2026-08-10 | 2026-11-12 |
| Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial Adebrelimab - Cervical Neoplasms | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 35 | 2026-08-01 | 2026-07-28 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-07-31 | 2026-07-29 |
| Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer Etoposide, Cisplatin, Carboplatin - Lung, Radiotherapy | Phase 2 | Recruiting | Jiangmen Central Hospital | 43 | 2026-07-20 | 2026-09-22 |
| Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC Adebrelimab, radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Chen Chunyan | 36 | 2026-05-01 | 2026-04-28 |
| Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer Trastuzumab Rezetecan, Adebrelimab, Lenvatinib - Biliary Tract Neoplasms Immunotherapy | Phase 2 | Recruiting | Peking Union Medical College Hospital | 70 | 2026-04-29 | 2026-06-26 |
| Adebrelimab Plus S-1 for Resected Cholangiocarcinoma Adebrelimab, S-1 - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Not yet recruiting | Xingjun Guo | 40 | 2026-04-21 | 2026-05-01 |
| Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer Trastuzumab Rezetecan, Adebrelimab, Lenvatinib - Biliary Tract Neoplasms Immunotherapy | Phase 2 | Recruiting | Peking Union Medical College Hospital | 70 | 2026-04-15 | 2026-07-15 |
| Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab - Adebrelimab (SHR-1316), Bevacizumab | Phase 2 | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-04-10 | 2026-04-28 |
Showing 20 of 101. Sign in to see all of them.
Small Cell Lung Carcinoma (8) · Biliary Tract Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (7) · Cholangiocarcinoma (5) · Esophageal Squamous Cell Carcinoma (5) · Pancreatic Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4) · Breast Neoplasms (3) · Esophageal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Rectal Neoplasms (2)
The First Affiliated Hospital with Nanjing Medical University (7) · Fudan University (6) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (6) · Tianjin Medical University Cancer Institute and Hospital (6) · Fujian Cancer Hospital (4) · Harbin Medical University (4) · Henan Cancer Hospital (3) · Shanghai Hengrui Pharmaceutical Co., Ltd. (3) · Sun Yat-sen University (3) · Tongji Hospital (3) · Peking Union Medical College Hospital (2) · The Affiliated Hospital of Putian University (2) · The First Affiliated Hospital of Xiamen University (2) · Zhangzhou Municipal Hospital (2) · Air Force Military Medical University, China (1)
China (77)
Bo Liu, Professor (1) · Changqing Jing, Professor (1) · Chong Deng (1) · Chunyan Chen (1) · Da Chen, MD&PhD (1) · Dezhi Li, MD&PhD (1) · Fang Liu, MD (1) · Feng Cheng, MD (1) · Guangyuan Hu, Doctor (1) · Guoqin Qiu (1) · Hao Xu, Ph.D (1) · Hecheng Li, MD, PhD (1) · Hongxia Wang (1) · Hongxia Wang, Chief physician (1) · Huita Wu (1)
PMID 29366520, PMID 32716739, PMID 36434949, PMID 36529152, PMID 37011232, PMID 39252865, PMID 41730557, PMID 41816563